panitumumab, regorafenib, and ziv-aflibercept in metastatic colorectal cancer
Published 10 years ago • 938 plays • Length 11:36Download video MP4
Download video MP3
Similar videos
-
9:00
first- and later-line use of panitumumab in metastatic colorectal cancer
-
10:02
role of the multikinase inhibitor regorafenib in metastatic colorectal cancer
-
5:25
second-line and salvage treatment of metastatic colorectal cancer
-
6:26
role of the vegf inhibitor aflibercept in metastatic colorectal cancer
-
1:04
dr. randall holcombe discusses regorafenib for metastatic colorectal cancer
-
8:14
optimizing treatment with regorafenib in metastic colorectal cancer
-
9:34
regorafenib in colorectal cancer
-
8:47
colorectal cancer: dosing strategies with regorafenib
-
5:32
colorectal cancer: regorafenib patient selection and dosing
-
8:26
regorafenib in advanced colorectal cancer: dosing strategies
-
1:36
optimal dosing of regorafenib in colorectal cancer
-
3:53
regorafenib in colorectal cancer: optimizing the dose
-
0:57
dr. peeters discusses the efficacy and safety of panitumumab versus cetuximab in colorectal cancer
-
2:52
metastatic colorectal cancer: trifluridine/tiripacil or regorafenib?
-
3:54
colorectal cancer: patient follow-up with regorafenib
-
3:14
when you have decided to prescribe regorafenib
-
7:35
use of regorafenib in refractory mcrc
-
1:05
dr. peeters on the utility of aflibercept in advanced colorectal cancer
-
1:30
dr. nancy l. lewis discusses the correct trial for regorafenib in metastatic colorectal cancer